ycanth
Generic: cantharidin·Code: VP-102
ycanth: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) | Phase 3 |
FDA Decisions
Approval1 INDICATIONS AND USAGE YCANTH is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older. YCANTH is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older. ( 1 )(VRCA)
Frequently asked questions
Who is developing ycanth?
ycanth is being developed by Verrica Pharmaceuticals Inc..
What is ycanth's latest FDA decision?
The most recent tracked FDA decision for ycanth is Approval for 1 INDICATIONS AND USAGE YCANTH is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older. YCANTH is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older. ( 1 ), dated July 21, 2023.
Get deeper analysis on ycanth
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis